FDA's Regulations on E-cigarette Industry: Chinese Company's Response

Aug.08.2022
FDA's Regulations on E-cigarette Industry: Chinese Company's Response
The FDA has issued over 263 marketing denial orders (MDO) to e-cigarette companies, prompting appeals and legal battles.

Editor's note: As of July 2022, the FDA has issued marketing denial orders (MDOs) to 263 electronic cigarette companies, prohibiting the sale of their products in the United States, and has rejected over a million PMTA applications. This has led to over 40 e-cigarette companies appealing to the FDA to suspend or revoke the MDOs, with the appeal review scheduled for 2025. Huang Zhuohao, a senior consultant at the Shanghai office of the law firm Two Supreme Invited Fangda, has proposed solutions to address the US electronic cigarette regulatory policy.


Author's Bio:


Huáng Zhuōhào, a senior advisor at the Shanghai office of Fangda Law Firm and a licensed lawyer in the state of New York, USA.


The following is the original text, with added subheadings by the editor:


The FDA and E-cigarette Enterprises in Tobacco Control Act.


On July 26, 2022, the United States Court of Appeals for the District of Columbia denied a rehearing request from four electronic cigarette manufacturers: Jucice Co., Cool Breeze Vapor, Ecig Charleston, and Jay Shore Liquids.


Four companies had submitted a Premarket Tobacco Application (PMTA) to the United States Food and Drug Administration (FDA) in 2020, but all received a Market Denied Order (MDO) from the FDA in 2021. The court acknowledged the FDA's decision that there was no evidence to prove that the electronic cigarette products of these four manufacturers met the requirements of the federal Family Smoking Prevention and Tobacco Control Act, which stipulates that they must be "appropriate for the protection of public health.


In 2009, US President Obama signed the Tobacco Control Act, which authorized the FDA to regulate tobacco products. All tobacco products sold in the US are required to submit a premarket tobacco product application (PMTA), evaluated by the FDA based on toxicology, packaging, advertising, and other sales strategies to determine if the product is "appropriate for public health protection." Products that meet the criteria are granted a Market Granted Order (MGO), while those that don't receive a Market Denied Order (MDO). In 2016, e-cigarettes were included in the category of tobacco products and must now also submit PMTA and receive approval. Products that fail to submit PMTA or receive a MDO will be prohibited from importation and sale in the US market, with violators facing warnings or fines.


According to official data released by the FDA, as of July 6, 2022, the FDA has only approved PMTA and granted MGO for a total of 23 e-cigarette products from three companies: U.S.-based R.J. Reynolds Vapor Company (9), Japan-based Logic Technology Development LLC (8), and China-based NJOY LLC (6). At the same time, MDOs have been issued to 263 e-cigarette manufacturers and sellers. Over 40 e-cigarette companies have appealed against the FDA's MDO, which the courts usually suspend pending a full review. While most of these appeals are still in the court or FDA's supplementary review stage, they have put considerable pressure on the FDA, and even resulted in the voluntary suspension of some MDOs. It is foreseeable that in the near future there will be instances of the courts rejecting FDA's MDO.


Lessons from Chinese business practices


What are the implications of this series of lawsuits for Chinese companies?


Currently, a substantial number of Chinese e-cigarette products have not yet applied for PMTA or have applied but received MDO. As a result, the import and sale of these products in the United States have lost their legal basis. While the FDA's enforcement of these products is currently limited to warnings and fines, strict measures are likely to be implemented in the future. Recent reactions from various American e-cigarette companies suggest that the cessation of imports and sales is only a matter of time. This will have a significant impact on the entire Chinese e-cigarette industry.


Chinese e-cigarette companies should consider taking action as soon as possible before strong law enforcement arrives, using the rules of America's game to leverage a larger living space for themselves. Currently, the FDA's enforcement of e-cigarettes in the United States appears to be a legal issue, but behind it is America's policy orientation toward the entire industry. The core issue is how much range is allowed for the e-cigarette industry to survive in the United States. Therefore, companies need to actively respond in both the legal and policy domains.


From a legal standpoint, businesses need to actively sue the FDA for any improper administrative actions and use litigation as a means to pressure the FDA into reaching a settlement with the company. Litigation has long been the primary weapon used by American companies to combat excessive governmental abuse of power. In fact, e-cigarette giant Juul used litigation last month to force the FDA to suspend its marketing denial order and continue legally selling products in the US. Through litigation, Juul also opened up negotiations with the FDA and provided a path for potential settlements in the future.


From a policy perspective, businesses can increase their negotiation leverage by adopting practices that align with American culture and gradually shifting the policy direction. Legitimate channels, such as collaborating with American stakeholders, engaging with the media, government officials and lawmakers, and connecting with independent research organizations can be used to legitimately voice out opinions and influence e-cigarette policies in the United States. Additionally, measures aimed at improving company governance and reputation overseas can strengthen the e-cigarette industry's policy bargaining power.


Currently, the United States is enforcing laws targeting the entire electronic cigarette industry, with intertwined economic interests at play. Chinese companies will only be able to fundamentally change the policy direction of the electronic cigarette industry in the United States by joining forces, coordinating resources, and collaborating effectively.


To learn more about the legal disputes between the FDA and e-cigarette companies, click on the "FDA and E-Cigarette Company Legal Dispute Summary" topic, which is being continually updated by 2FIRSTS.


Risk Alert and Disclaimer:


This article is authorized by the author for first publication on "2FIRSTS". The views expressed in the article solely represent the author's personal opinion. The title and editorial modifications are made by the editors at "2FIRSTS". Please refer to the original text from the author for the content of the article.


This article pertains to e-cigarette policies, and readers are advised to consult official documents released by the governments of China and relevant countries for accurate information. The data and policies presented by the author in this article cannot be verified by 2FIRSTS, so caution is advised when reading.


This article is intended for industry researchers only. Please refrain from forwarding it to individuals outside of the industry or to minors.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands reported an 11.4% increase in next-generation product (NGP) net revenue to £419 million in fiscal 2026, while its adjusted NGP operating loss narrowed to £63 million. European NGP revenue rose 16.8%, while the Americas recorded a 17.1% decline. Global modern oral nicotine volumes increased 27.8%, with US nicotine pouch brand Zone expanding to approximately 114,000 stores. The company also acquired Black Buffalo in the US and Helwit in Sweden, broadening its oral nicotine portfolio. From FY2027, Imperial Brands will adopt a new Smokeless reporting category combining NGP with traditional oral tobacco. On the new basis, FY2026 Smokeless net revenue was £554 million, with adjusted operating profit of £14 million.
company
Nov.18
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
During its coverage of Altria's booth at NACS Show 2026, 2Firsts documented product displays that prompted questions about U.S. tobacco advertising warning requirements. Following public comments from a former FDA official, 2Firsts sought responses from Altria and independently consulted U.S. regulatory lawyer Azim Chowdhury. Altria maintained that its B2B communications complied with applicable laws, while Chowdhury explained that federal warning rules provide no general trade-show exemption for e-cigarettes and nicotine pouches. The special report examines the broader regulatory implications.
Nov.04
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Philip Morris International (PMI) is expanding the international footprint of BONDS by IQOS, its lower-priced heated tobacco platform. The company's third-quarter 2026 SEC filing shows that BONDS devices and BLENDS tobacco sticks were available in 15 markets at the end of September, up from eight at the end of June. In November, PMI announced plans to extend sales from three to 17 Japanese prefectures and introduced BONDS in Spain and Morocco. The platform uses ROUNDHEAT external heating technology and proprietary tobacco sticks, separate from the IQOS ILUMA system. In Japan, BONDS retails for ¥2,980, approximately 25% below ILUMA i ONE, while BLENDS costs ¥570 per pack. PMI management says BONDS targets cigarette smokers who have not adopted heated tobacco. Separate sales and revenue figures remain undisclosed.
company
Nov.06
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands (TPB) reported third-quarter 2026 Modern Oral net sales of $74.4 million on November 9, up 102.9% year over year and representing 49.2% of consolidated net sales. Total company net sales rose 27.0% to $151.1 million, while net income attributable to TPB declined 81.4% to $3.93 million. The company is expanding the US retail presence of its FRE and ALP nicotine pouch brands and expects its Modern Oral chain-store footprint to grow by more than 70% during 2026. Selling, general and administrative expenses increased 69.1% to $75.3 million, while PMTA-related expenses reached approximately $3.15 million and manufacturing start-up costs totaled about $593,000. ALP plans to open a branded pop-up in New York City's SoHo neighborhood on November 13, alongside a marketing campaign extending into January 2027. TPB owns 50% of ALP but consolidates the venture in its financial statements.
company
Nov.11